Analysis of Volatile Organic Compounds
Customize your policy alerts
Sign up for Aetna Policy 0717 alerts
Get alerted when Policy 0717 changes without checking for updates manually.
Monitor payer policy activity
This policy governs the coverage stance for tests that analyze volatile organic compounds (VOCs) in biologic specimens (e.g., urine, blood, breath) for diagnosis, screening, or monitoring of disease. It affects providers and laboratories submitting claims to Aetna for VOC analysis.
Coverage Criteria
Experimental and Investigational
Not covered (considered experimental and investigational) for the following indications because clinical effectiveness has not been established:
List not exhaustive
Conditional coverage requirements
Coverage stance is conditional on validation and standardization
Validation and standardization required
- 1.: Assay method and sample collection are standardized and documented (including sample medium and collection/handling procedures).
- 2.: Diagnostic performance is validated in independent external cohorts with appropriate reference standards (e.g., culture for UTI, colonoscopy for CRC).
- 3.: Prospective studies demonstrate clinical utility and impact on patient outcomes, including assessment of reproducibility across centers and analytic platforms.
Evidence summaries (informational, not coverage rules)
Summary of evidence-based considerations (informational):
This policy explicitly lists a wide range of clinical indications for which analysis of volatile organic compounds (VOCs) is considered experimental and investigational because clinical effectiveness has not been established. Examples include detection of bacteriuria; detection of bronchiolitis obliterans syndrome after lung transplant; detection, diagnosis, or monitoring of multiple cancers (bladder, breast, colorectal, esophagogastric, gallbladder, gastric, hepatobiliary, lung, pancreatic, renal, pleural malignancies); diagnosis and monitoring of pleural mesothelioma and sarcoidosis; several metabolic, inflammatory, infectious, pediatric and neurologic conditions (e.g., alcoholic hepatitis, autism spectrum disorders, celiac disease, idiopathic membranous nephropathy, inflammatory bowel disease, juvenile idiopathic arthritis, asthma, amyotrophic lateral sclerosis); prediction of asthma exacerbations, childhood obesity, or necrotizing enterocolitis; screening for COVID‑19; use as biomarkers for COPD; and monitoring hemodialysis efficiency. The list is not exhaustive and the policy treats these uses as investigational and excluded from routine coverage.
Exhaled VOCs and biomarkers in exhaled breath condensate are described in the policy as a research tool for pediatric respiratory diseases and are not validated for routine clinical use. The document highlights large literature searches with only a small fraction of original pediatric VOC studies and emphasizes lack of longitudinal data and external validation as barriers to clinical implementation.
The policy notes that many published studies of VOCs are observational, include small sample sizes, and are heterogeneous in design and sampling media. Systematic reviews cited in the policy report selection biases, inadequate reporting of clinical parameters (including cancer stage), and substantial methodological variation that limit the strength and generalizability of the evidence.
VOC tests that lack standardized collection and analytic methods, absence of external validation, or are limited to small pilot/case‑control studies are identified in the policy as not ready for routine clinical implementation and therefore unsupported for coverage until standardized and externally validated.
The policy emphasizes that variable sample collection protocols and analytic approaches—such as differences in sample containers, handling (e.g., immediate freezing for urine), timing, and analytical platforms—introduce heterogeneity that limits reproducibility and therefore undermines potential clinical impact of VOC testing.
This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and does not constitute a contract or medical advice; it may be updated and is subject to change. Providers should consult applicable plan documents and payer guidance for definitive coverage determinations.
Because available studies do not demonstrate established clinical effectiveness for the listed uses, analysis of volatile organic compounds for those indications is considered not medically necessary and is not supported for routine clinical coverage under this policy.
For pediatric respiratory diseases specifically, the policy states that exhaled VOC analysis and exhaled breath condensate biomarkers remain investigational; current evidence is insufficient to support clinical diagnostic or monitoring use in children.
The policy characterizes the overall evidence base for VOC assays as preliminary and heterogeneous: many studies are small, observational, and vary in sampling media and analytic technique, which limits interpretation of reported diagnostic performance and precludes adoption as standalone clinical tests.
The document advises against clinical implementation of VOC assays that lack external validation, standardized methods, and prospective outcome data. Clinical use should be restricted to validated tests and well‑designed prospective studies until reproducibility and clinical utility are demonstrated.
Heterogeneity in study design, modest overall study quality, and absence of multicenter validation limit the current utility of VOC‑based tests for screening or diagnosis (for example, colorectal cancer, COVID‑19, and tuberculosis). The policy underscores the need for standardized sampling, consistent analytic strategies, and external validation before routine clinical adoption.
Covered or Investigational Indications
None identified as covered
None identified as covered in this portion of the policy.
Investigational detection or differentiation of disease states
Most data are pilot or observational; external validation needed.
Investigational/diagnostic research use for various cancers
Investigation of COPD phenotypes and potential diagnostic biomarkers
Assessment of severe bronchiolitis obliterans syndrome (BOS) post-lung transplant
Profiling wound VOCs to identify causative bacteria and monitor healing
Exhaled breath profiling for ALS screening/diagnosis (proof-of-concept)
Research/experimental use for lung cancer, urinary VOCs for various cancers, and CRC screening adjunct to FIT
Investigation and monitoring of pleural mesothelioma in research settings
Investigational screening/detection of colorectal cancer, COVID-19, and tuberculosis — research/validation settings only
Research and reported diagnostic investigations of VOCs for many conditions
Not Covered
Analysis of volatile organic compounds for detection, diagnosis, screening, or monitoring for the multiple clinical indications listed in this policy is considered not covered because the clinical effectiveness of VOC analysis for these uses has not been established.
Routine clinical coverage of VOC‑based tests is not supported by the policy due to lack of standardization in collection and analysis methods and absence of sufficient external validation; many tests remain research tools rather than validated clinical assays.
The policy indicates that VOC profiles have not been established as validated, standalone diagnostic tests across reviewed conditions because methodological heterogeneity, small sample sizes, and limited external validation prevent confirmation of clinical validity and utility.
Methodological heterogeneity and predominance of small studies are repeatedly cited as limitations that restrict clinical adoption of VOC testing; these factors reduce reproducibility and the ability to generalize reported diagnostic metrics.
Tests that do not employ standardized methods, lack reproducibility, or have not undergone external validation are not supported for routine clinical screening or diagnostic use according to this policy.
Within the provided excerpts the policy does not enumerate a separate explicit list of specific commercially named tests that are categorically not covered; rather, the document frames noncoverage around indications and lack of validated methods and external validation.
Coding
| A15.0-A19.9 | Tuberculosis |
| B37.0 | Candidal stomatitis |
| C00.0-C96.9 | Malignant neoplasms |
| D00.1 | Carcinoma in situ of esophagus |
| D00.2 | Carcinoma in situ of stomach |
| D05.00-D05.92 | Carcinoma in situ of breast |
| D24.1-D24.9 | Benign neoplasm of breast |
| D48.60-D48.62 | Neoplasm of uncertain behavior of breast |
| D49.3 | Neoplasm of unspecified behavior of breast |
| D86.0-D86.89 | Sarcoidosis |
Provider Actions and Operational Notes
Coverage requires clinical effectiveness evidence
Coverage is contingent on demonstrated clinical effectiveness. VOC-based tests lacking adequate clinical outcome evidence are considered experimental/investigational and are at risk for denial when submitted for the indications listed in this policy.
- Tests without robust clinical effectiveness data may be denied.
- OMA-UTI has FDA 510(k) clearance but clinical efficacy evidence is limited and insufficient to establish routine coverage.
Validation requirement for clinical adoption
Prior to routine clinical adoption, VOC-based tests must undergo independent validation with standardized protocols and multicenter studies. Tests should demonstrate reproducible performance (sensitivity, specificity, AUC) across external cohorts before being used for clinical decision-making.
- Recommend multicenter external validation and protocol standardization.
- Report validation metrics (AUC, sensitivity, specificity) and whether findings were replicated in independent cohorts.
Prior authorization
Prior authorization may be required for VOC-based testing given the lack of standardized algorithms and variable evidence. Where prior authorization is applied, medical necessity must be documented and justified with validated evidence.
- No specific payer prior authorization rules are stated in the source — check plan-specific PA requirements.
- When PA is required, include supporting clinical evidence and rationale for testing.
Prior authorization for VOC-based tests
Given heterogeneous methods and the absence of standardized test algorithms for many VOC assays, payers may require prior authorization specifically for VOC-based tests until standardized, validated methods are available.
- Tests using non-standardized sampling/analysis lack consensus algorithms and are higher risk for noncoverage.
- Programs may require PA to ensure appropriate use and documentation.
Prior validation required before routine coverage
Prior validation in representative clinical populations and standardized procedures is required before routine coverage. Small, single-center studies or studies lacking external validation do not meet this requirement.
- Require external validation and reporting of sample media effects on performance.
- Multi-center validation and standardized protocols are recommended prior to coverage.
Experimental/Investigational indications trigger denial
Claims for indications listed as experimental and investigational (see policy list) are likely to be denied because clinical effectiveness has not been established.
- Examples include detection of bacteriuria, bronchiolitis obliterans syndrome, many cancers, and numerous diagnostic/monitoring uses listed in the policy.
- OMA-UTI is noted separately with 510(k) clearance but the broader class of VOC tests for listed indications remains investigational.
Standardization and validation required
Standardization of sample collection, handling, analytic platforms, and reporting is necessary. Without standardized methods (e.g., breath sampling, headspace sampling, adsorption/desorption protocols, GC-MS or SIFT‑MS parameters), results may be unreliable and not generalizable.
- Document and follow standardized breath/urine/bile sampling protocols.
- Control for site-specific differences and confounders (eg, smoking, storage conditions).
Not specified in this excerpt; no operational triggers provided
This excerpt does not specify operational billing, authorization triggers, or detailed plan-level procedures; check plan/provider materials for local operational requirements.
- No explicit payer prior authorization rules provided in this policy excerpt.
- Administrative links and policy history are present but do not list provider documentation checklists.
Risks tied to insufficient validation
Insufficient validation introduces risks including false positives/negatives, poor generalizability due to small sample sizes, and uncertain impact on clinical outcomes. These risks may lead to inappropriate clinical decisions and coverage denials.
- Small studies and lack of external validation increase the risk of unreliable performance.
- Inadequate reporting of clinical parameters (eg, disease stage) limits interpretation of clinical utility.
Heterogeneous methods risk noncoverage
Heterogeneous sampling media and analytic methods across studies contribute to inconsistent results and are a common reason for noncoverage until harmonized methodologies and reproducible performance are demonstrated.
- Sample media (breath, urine, bile) contributes to heterogeneity in performance.
- Lack of standardized analytic pipelines (fingerprinting vs chemical identification) impedes reproducibility.
No explicit authorization or denial triggers present
No explicit authorization or automatic denial triggers are stated in the provided policy text; operational decisions may depend on plan-specific administrative procedures and prior authorization criteria.
- Providers should confirm applicable PA requirements with the payer.
- The policy history and administrative links are available but do not define operational triggers.
Documentation re: FDA 510(k) and evidence
Although the OMA-UTI device has FDA 510(k) clearance (2001), the policy notes that 510(k) clearance does not require the level of clinical efficacy evidence needed for a PMA; clinical outcome studies are still necessary to establish effectiveness.
- OMA-UTI reported sensitivity/specificity ~81%/83% versus culture but broader clinical utility remains unproven.
- 510(k) clearance indicates substantial equivalence to a predicate device, not definitive clinical benefit evidence.
Required study/test documentation
When submitting studies or test reports, include detailed analytic and validation information: sample medium, collection/handling methods, analytic platform and settings, statistical methods, and validation metrics (AUC, sensitivity, specificity, confidence intervals).
- Report whether findings were validated in independent cohorts and provide external validation data.
- Include details on sample storage (eg, sealed containers, freezing, analysis within recommended timeframe) when applicable.
Documentation of sampling and methods
Document sampling and breath/biologic-specimen methods explicitly: type of sample (breath, urine, bile), collection device, pre-collection conditions (fasting, room air inhalation), adsorption/desorption media, storage conditions, and timing between collection and analysis.
- For breath: note reservoir or adsorption approach, controlled inhalation/exhalation protocol, and pre-sampling controls (eg, no smoking).
- For urine/bile: record container sealing, freezing, and time-to-analysis (recommend within 9–12 months for urine when frozen).
Required test documentation: sample handling and analytic details
Required test documentation should also include handling details (collection method, sealing, freezing), analytic pipeline (fingerprinting vs chemical identification), algorithms used for classification, and whether multicenter standard operating procedures were followed.
- Specify whether chemical identification or fingerprinting was performed and provide compound identification where available.
- Include algorithm/feature selection and classifier performance with cross-validation and external validation results.
This section contains administrative links and policy history
This section includes administrative links, policy history, and notices but does not provide a provider checklist for documentation or explicit operational billing guidance. Providers should consult plan portals for those operational details.
- Administrative links: Review History, Definitions, Clinical Policy Bulletin Notes are referenced.
- Policy effective date and next review are listed but operational procedures are not detailed in this excerpt.
Use standard diagnostic pathway before VOC testing
Use established diagnostic pathways (eg, urinalysis and culture with CFU thresholds for UTI) before considering VOC testing as an adjunct. VOC tests should not replace standard diagnostic algorithms until validated evidence supports such changes.
- For UTI: rely on urinalysis and culture (classical threshold 100,000 CFU/ml for voided specimens) as primary diagnostics.
- Consider VOC testing only as adjunctive and only when validated and documented appropriately.
Combination testing considerations
Combination testing (eg, FIT plus VOC for colorectal cancer detection) has shown potential to increase detection in some studies, but standardized methods, external validation, and cost-effectiveness analyses are required before routine adoption.
- Combined FIT‑VOC testing improved CRC detection in pooled analyses but requires prospective validation in real-life screening settings.
- Assess cost-effectiveness and standardize sample/analysis protocols prior to payer coverage.
Ordering Requirements
Order established diagnostic tests (urinalysis/culture) as standard pathway
Standard diagnostic tests (urinalysis and culture with classical thresholds such as ≥100,000 CFU/ml for voided specimens) remain the established ordering pathway; VOC testing has not supplanted these standards.
No explicit ordering‑clinician restrictions specified
The policy does not specify restrictions on which clinicians may order VOC tests; no explicit ordering clinician limitations are provided in these excerpts.
Ensure validated sampling methods and documented analytic platforms when ordering
Ordering clinicians should ensure that sampling methods and analytical platforms are validated and documented in the laboratory’s reports before relying on VOC test results for clinical decision‑making.
Limit ordering to validated studies or labs with standardized methods
Limit ordering of VOC testing to validated clinical studies or laboratories that document standardized collection and analytic protocols and external validation; routine clinical ordering is discouraged until such validation exists.
Use defined protocols and reference standards in research/validation studies
Research and validation studies should follow defined protocols and appropriate reference standards (for example colonoscopy as the reference standard for colorectal cancer screening) when using VOCs in investigational settings.
No specified restrictions on who may order VOC tests in these excerpts
The provided chunks do not specify who may order VOC tests; ordering‑provider qualifications are not described in these excerpts.
Frequency Limits
Background and Definitions
Volatile organic compounds (VOCs) are emitted from biological samples such as breath, urine, and other bodily fluids and have been investigated as noninvasive biomarkers for infections, cancer, metabolic and inflammatory diseases. The policy recognizes VOC analysis as an investigational approach in many contexts and describes analytical platforms (for example, electronic nose technologies) that have been explored in research settings but not established for routine clinical use.
Research Evidence Highlights
Supporting the policy’s coverage stance, cited reviews and studies report that much of the VOC literature is preliminary, with small, observational, and heterogeneous studies; inadequate reporting of clinical parameters and limited external validation reduce confidence in reported diagnostic performance and highlight the need for standardized prospective studies.
Revision History
Policy became effective.
Most recent policy review conducted.
Next policy review scheduled.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.